Skip to main content

High Triglycerides

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
LovazaPhase 4
NorthSea Therapeutics
NorthSea TherapeuticsNetherlands - Amsterdam
1 program
1
NST-1024Phase 21 trial
Active Trials
NCT05889156Completed50Est. Apr 2025
GSK
GSKLONDON, United Kingdom
1 program
LovazaPHASE_41 trial
Active Trials
NCT00833976Completed65Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKLovaza
NorthSea TherapeuticsNST-1024

Clinical Trials (2)

Total enrollment: 115 patients across 2 trials

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

Start: Jul 2009Est. completion: Mar 201365 patients
Phase 4Completed

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

Start: Jun 2023Est. completion: Apr 202550 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.